Implantable article, method of forming same and method for reducing thrombogenicity

Abstract
Endothelialization of a bodily fluid or tissue-contacting, particularly blood-contacting, surface may be accomplished to render that surface substantially non-thrombogenic. Thrombosis may also be mitigated or eliminated by providing an eroding layer on the surface that results in the removal of any thrombus formation as the layer erodes. An implantable device may utilize at least one surface having a plurality of nano-craters thereon that enhance or promote endothelialization. Additionally, an implantable device may have at least one first degradable layer for contacting bodily fluid or tissue and disposed about a central core, and at least one second degradable layer between the first degradable layer and the central core. The first degradable layer has a first degradation rate and the second degradable layer has a second degradation rate which degrades more slowly than the first degradable layer on contact with bodily fluid or tissue.
Description
FIELD OF THE INVENTION

The present invention relates generally to implantable devices, such as implantable medical devices, and methods for the manufacture thereof. The invention also relates to methods for enhancing and promoting endothelialization and for minimizing thrombus formation on the surface of the implantable device.


BACKGROUND OF THE INVENTION

In recent years there has been growing interest in the use of artificial materials, particularly materials formed from polymers, for use in implantable devices that come into contact with bodily tissues or fluids particularly blood. Some examples of such devices are artificial heart valves, stents and vascular prosthesis. Progress in this area has, however, been hampered somewhat by the thrombogenicity of many polymer materials. Reference is made to M. Szycher, J. Biomat Appln (1998) 12: 321 in that regard.


Efforts to overcome the problems associated with thrombogenicity of polymer materials used in the production of implantable devices have not met with a great deal of success to date. Some examples of approaches that have bee attempted include heparinization (S. W. Kim, C. D. Ebert, J. Y. Lin, J. C. McRea Am Soc Artif Internal Organs (1983) 6: 76), physical modification of the surface (K. Webb, W. Hlady, P. A Tresco, J. Biomed Mat Res (1998) 41: 421-430; E. W. Merrill, Ann NY Acad Sci (1977) 6: 283-290) and increasing surface hydrophilicity (S. J. Sofia, E. W. Merrill, in “Polyethylene Glycol; Chemistry and Biological Applications”, J. M. Harris and S. Zalipsky (eds.), American Chemical Society (1997) Ch. 22). Although these methods have met with some commercial viability, they are mainly useful for short-term applications, such as in catheter or in dialysis tubing. This is because many of the chemical and physical modifications of the device surfaces have limited shelf-life, both ex vivo and in vivo. Moreover, the methods involved in the production of implantable devices using these approaches are both elaborate and intricate.


Attempts have also been made to minimize thrombus formation by promoting endothelialization of the surface of an implantable device that contacts bodily fluids or tissues in use as described, for example, in U.S. Pat. No. 5,744,515, which relates to modification of a porous material with adhesion molecules, and U.S. Pat. No. 6,379,383, which relates to deposition of the material used to form the device so as to control surface heterogenities.


SUMMARY OF THE INVENTION

Thrombus formation is a very complex process involving inter-dependent interactions between a surface of an implantable device, platelets and coagulation proteins. The present invention addresses the problem of thrombosis by endothelialization of a bodily fluid or tissue-contacting, particularly blood-contacting, surface to render that surface substantially non-thrombogenic. The invention also addresses the problem of thrombosis by providing an eroding layer on the surface that results in the removal of any thrombus formation as the layer erodes.


According to one aspect of the invention, there is provided an implantable device having at least one surface for contacting bodily fluid or tissue, said at least one surface comprising a plurality of nano-craters thereon that enhance or promote endothelialization of said at last one surface.


According to one aspect of the invention, there is provided an implantable device having at least one first degradable layer providing at least one surface of the implantable device for contacting bodily fluid or tissue and disposed about a central core, and at least one second degradable layer between said first degradable layer and the central core, wherein said first degradable layer has a first degradation rate and said second degradable layer has a second degradation rate such that said at least one first degradable layer degrades more rapidly than said at least one second degradable layer on contact with bodily fluid or tissue.


The material of the implantable device is not particularly limited. Furthermore, the nano-craters may be formed in the material that constitutes the body of the implantable device, or may be formed in a layer that is applied to a support substrate forming the implantable device. Generally, the nano-craters will be formed in a surface layer of suitable biocompatible material applied to a support structure for the implantable device. The options for the biocompatible material forming the outer layer of the implantable device are generally known and are discussed hereafter.


The form of the implantable device is similarly not particularly limited. This may include any device that is intended to come into contact with bodily fluids or tissues, be that during in vivo applications or in vitro applications. Examples of particular devices will be provided hereafter.


According to further aspect of the invention, there is provided a method of Manufacturing an implantable device having at least one surface for contacting bodily fluid or tissue comprising: providing on said at least one surface a plurality of nano-craters that enhance or promote endothelialization of said at least one surface.


According to a further aspect of the invention, there is provided a method of reducing thrombogenicity of an implantable device having at least one surface for contacting bodily fluid or tissue, or promoting or enhancing endothelialization of an implantable device having at least one surface for contacting bodily fluid or tissue, comprising: providing on said at least one surface a plurality of nano-craters that enhance or promote endothelialization of said at least one surface.


According to another aspect of the invention, there is provided a method of manufacturing an implantable device having at least one surface for contacting bodily fluid or tissue, comprising: providing at least one first degradable layer which provides said at least one surface and which is disposed about a central core, and at least one second degradable layer between said first degradable layer and the central core, wherein said first degradable layer has a first degradation rate and second degradable layer has a second degradation rate such that said at least one first degradable layer degrades more rapidly than said at least one second degradable layer on contact with bodily fluid or tissue.


According to still another aspect of the invention, there is provided a method of reducing thrombogenicity of an implantable device having at least one surface for contacting bodily fluid or tissue, comprising: providing at least one first degradable layer which provides said at least one surface and which is disposed about a central core, and at least one second degradable layer between said first degradable layer and the central core, wherein said first degradable layer has a first degradation rate and said second degradable layer has a second degradation rate such that said at least one first degradable layer degrades more rapidly than said at least one second degradable layer on contact with bodily fluid or tissue.


Other aspects and features of the present invention will become apparent to those of ordinary skill in the art upon review of the following description of specific embodiments of the invention in conjunction with the accompanying figures.





BRIEF DESCRIPTION OF THE DRAWINGS

In the figures, which illustrate, by way of example only, embodiments of the present invention,



FIG. 1 is a schematic representation of an implantable device having nano-craters on the surface of the device; and



FIG. 2 is a Schematic diagram of a process to form nano-craters in a surface using a mask and etching techniques;



FIG. 3 is a schematic representation of an implantable device having two degradable layers.



FIG. 4 illustrates some of the results of the number of cells correlated to pore size in a PLLA polymer.



FIG. 5 also illustrates some of the results of the number of cells correlated to pore size in a PLGA polymer sample.



FIG. 6 illustrates results correlating inter-pore distance to cell attachment and growth of the endothelial cells.





DETAILED DESCRIPTION OF THE INVENTION

When a bodily fluids-contacting or tissue-contacting, particularly blood-contacting, surface is coated with endothelial cells, it is rendered substantially non-thrombogenic. Thus, in one aspect, the reduced thrombogenicity of an implantable device is achieved by enhancing and/or promoting endothelialization of the surface of the implantable device that contacts bodily fluid or tissue.


This aspect of the invention is based on the surprising discovery that the inclusion of nano-craters on a surface of an implantable device that is intended to come into contact with bodily fluids or tissues, such as blood, advantageously improves endothelial cell attachment to the surface. The inclusion of the nano-craters therefore assists in the propagation of endothelial cells on the surface of the device. It is believed that the improved attachment and propagation of endothelial cells on the surface is a result of the nano-craters on the surface acting as foci for endothelial cell attachment. This aspect of the invention is particularly suited for manufacture of implantable devices that are intended to be in long-term contact with bodily fluids or tissues, particularly in long-term contact with blood.


In another aspect, the reduced thrombogenicity is achieved by providing a surface layer that degrades in a controlled fashion, such that any thrombus that is formed at the surface is removed as the surface layer degrades. This aspect of the invention is based on the discovery that by providing the surface with layers having different degradation rates, it is possible to remove any thrombus formed on the surface in a controlled fashion, by degradation of each successive layer. This aspect of the invention is particularly suited for manufacture of implantable devices that are intended to be in short-term contact with bodily fluids or tissues, particularly blood.


The implantable device described herein may be any device that would benefit from the reduced thrombogenicity of a surface, including by enhancement of the endothelialization of a surface or by degradation of surface that comes in contact with bodily fluid or tissue, as described below, so as to reduce or remove thrombus formation on such a surface, particularly where such a surface is a blood-contacting surface, when the device is in use.


As used herein, the term “implantable device”, which may also be referred to as a “device” or a “medical device”, refers to any device having at least one surface that comes in contact with bodily tissue or fluid, including blood, and includes a device for implanting in a subject's body, permanently or temporarily, long-term or short-term. The term, as used herein, also refers to any device that forms a part of an article.


It is envisaged that the device is useful not only for in vivo applications, but also in vitro applications. As such, the device is not particularly limited, but should be considered to include any device that is intended for contact with bodily fluids or tissues, particularly blood, including conduits, grafts, valves, dialysis tubing and stents. As used herein the term “bodily fluids or tissues” includes biologically derived fluids and tissues as well as synthetic substitutes, for example artificial blood.


As used herein, the term “endothelialization” refers to the growth and/or proliferation of endothelial cells on a surface, such as the blood-contacting surface, or an implantable device. Promoting or enhancing endothelialization of a surface refers to promoting, enhancing, facilitation or increasing the attachment of, and growth of, endothelial cells on the surface.


As would be appreciated by a skilled person, the surface of a device for implantation into a subject is preferably biocompatible. The term “biocompatible” means that a substance is minimally toxic or irritating to biological tissue, such as to be sufficiently tolerated in the body without adverse effect. The surface may be formed of a material, which is different from the material that forms the surface and which is used as a support. Alternatively, the device and surface may be formed of the same material.


Suitable materials for forming the surface include biostable polymers, for example, polyethylene, polyurethane, polyolefin, or polyethylene terephthalate and degradable polymers, including degradable by chemical means or by exposure to radiation, for example, poly-lactide (PLA) including poly-L-lactide (PLLA), poly-glycolide (PGA), poly(lactide-co-glycolide) (PLGA) or polycaprolactone. In certain other embodiments, the degradable polymer may be biodegradable, meaning that the substance will readily degrade in an environment that is, or that is equivalent to, the body of a subject, for example when in contact with bodily fluid or tissue.


Other suitable materials that can be used to form an implantable device, or to provide the surface of an implantable device, are generally known in the art and examples of such materials are outlined in U.S. Pat. No. 5,744,515, which is herein incorporated by reference. For example, preferred materials include synthetic polymers, including oligomers, homopolymers, and copolymers resulting from either addition or condensation polymerization. Examples of suitable addition polymers include, but are not limited to, acrylics such as those polymerized from methyl cerylate, methyl methacrylate, acrylic acid, methacrylic acid, acrylamide, hydroxyethyl acrylate, hydroxyethyl methacrylate, glyceryl scrylate, glyceryl methacrylate, methacrylamide and methacrylamide; vinyls such as styrene, vinyl chloride, binaly pyrrolidone, polyvinyl alcohol, and vinyls acetate; polymers formed of ethylene, propylene, and tetrafluoroethylene. Examples of condensation polymers include, but are not limited to, nylons such as polycaprolactam, polylauryl lactam, polyhexamethylene adipamide, and polyhexamethylene dodecanediamide, and also polyurethanes, polycarbonates, polyamides, polysulfones, poly(ethylene terephthalate), polylactic acid, polyglycolic acid, polydimethylsiloxanes, and polyetherketones.


Other suitable materials include metals and ceramics. The materials include, but are not limited to, nickel, titanium, nickel-titanium alloys such as Nitinol, stainless steel, cobalt and chromium. The ceramics include, but are not limited to, silicon nitride, silicon carbide, zirconia, and alumina, as well as glass and silica, ePTFE (Expanded polytetrafluoroethylene) is a preferred substrate material for use in fabricating implantable devices of the present invention, and particularly for fabricating vascular grafts. Suitable ePTFE is available in the form of vascular grafts from such sources as IMPRA, Inc., Tempe, Ariz. Commercially available grafts are constructed of ePTFE and supplied in sterile form in a variety of configurations, including straight, tapered and stepped configurations.


Referring to FIG. 1, in the depicted embodiment, device 100 is stent, with an exterior surface 102a and an interior surface 102b which lines the lumen of the stent, both of which have reduced thrombogenicity meaning that they have a reduced tendency to promote, induce or facilitate formation of thrombi when in contact with bodily fluid or tissue. In the case of a coronary stent, since surface 102b contacts blood, including platelets, it is particularly important that surface 102b be rendered less thrombogenic, as described herein.


Device 100, in one particular variation, may comprise a polymeric stent fabricated as disclosed in U.S. patent application Ser. No. 10/867,617 filed Jun. 15, 2004 (U.S. Pat. Pub. 2005/0021131 A1), which is incorporated herein by reference in its entirety. The stent, as shown and described, may comprise a polymer that is at least partially amorphous and which undergoes a transition from a pliable, elastic state at a first higher temperature to a brittle glass-like state at a second lower temperature as it transitions through a particular glass transition temperature. This particular stent may be comprised of at least a first layer and a second layer where the first layer includes a first polymer that is at least partially amorphous and a second layer that is also at least partially amorphous. The stent may be formed to have a first shape at a relatively lower temperature and a second shape at a relatively higher temperature. The inner and/or outer layer of the stent 100 may be processed to have nano-crater 104 as described herein.


A substantially uniform layer of nano-craters 104 are distributed on surface 102a and 102b, meaning that nano-craters 104 of substantially similar depth are distributed on the surfaces 102a and 102b to form a discernible layer having such nano-craters. It has advantageously been found that the provision of such nano-craters 104 enhances endothelialization of surface 102a and 102b, resulting in reduced thrombogenicity. The stent 100 is suitable for long-term implantation in the body of a subject.


As used herein, the term “nano-crater” means indentations or depressions provided on a surface. Generally the indentations are on the nanometer scale. In different embodiments, the nano-craters have an average diameter of between about 30 nm and about 150 nm.


The stent 100 has nano-craters 104 sufficiently distributed over surfaces 102a and 102b to promote or enhance endothelialization, preferably over the entirety of surface 102a and 102b. The nano-craters 104 may be regularly or irregularly distributed over surfaces 102a and 102b. In some embodiments, adjacent craters may be spaced about 200 nm or greater apart.


Such nano-craters 104 may be suitably shaped, having a regular or irregular shape, provide that endothelialization of the surfaces 102a and 102b having the nano-craters 104 is enhanced and/or promoted. For example, the nano-craters 104 may be hemi-spherical, hemi-cylindrical or elliptical.


The size and shape of the nano-craters 104 can be controlled to provide a unique surface morphology. By varying this surface morphology, the range of sizes that selectively promote endothelial cell attachment while not being reception to platelet attachment, can be readily ascertained.


Optionally, surfaces 102a and 102b of the stent 100 can be chemically modified so as to further enhance or promote endothelialization, for example when implanted in a subject's body.


By way of background, it is noted that there are two ways by which an implanted device or surface can be covered with endothelial cells. In the first, called the transmural or capillary endothelialization, endothelial cells migrate into the device from tissue that is external to (usually above or below) the implanted device. For this sort of endothelialization to occur, the device itself must be sufficiently porous to permit the endothelial cells to migrate into it. A coronary stent such as the Palmaz stent (U.S. Pat. No. 6,379,383) is an example of such a device. This type of endothelialization may be achieved by coating an implantable device with a radiation-sensitive bioerodible polymer followed by irradiation with an electron beam to generate the nano-craters, as it set out below.


The second method of endothelialization involves migration of endothelial cells longitudinally into the device (e.g., in the lumen of a stent implanted in a blood vessel) from tissue adjacent to the device. In this case, porosity of the implantable device is not required, as endothelial cell attachment occurs from within a lumen or cavity of the device. However, the number of endothelial cells that are capable of this type of attachment is lower than those that can be achieved by transmural endothelialization.


Hence, it is envisaged that while the nano-cratered surfaces will enhance selective endothelial cell attachment on non-porous devices, the production and attachment of these endothelial cells in vivo may be enhanced using certain growth-stimulating molecules and adhesion-promoting molecules.


As used herein, the term “growth-stimulating molecule” refers to a molecule that stimulates or induces the differentiation, growth and proliferation of endothelial cells. Growth-stimulating molecules include peptides, proteins and glycoproteins, including hormones, capable of inducing an endothelial cell to grow and divide.


As used herein, the term “adhesion-promoting molecule” refers to a molecule that promotes or encourages adhesion or attachment of an endothelial cell to a surface. Adhesion-promoting molecules include peptides, proteins and glycoproteins capable of binding a cell to a substrate or to an adjacent cell.


As such, according to certain embodiments, surfaces 102a and 102b of the stent 100 include growth-stimulating molecules and/or adhesion-promoting molecules dispersed therein, which facilitate enhanced production of endothelial cells and their attachment to the nano-cratered surfaces 102a and 102b.


Suitable growth-stimulating molecules include granulocyte colony stimulating factor (gCSF), platelet-derived endothelial cell growth factor (PD-ECGF), fibroblast-derived endothelial cell growth factor alpha, endothelial cell growth factor beta, endothelial cell growth factor 2a and endothelial call growth factor 2b.


Suitable adhesion molecules are described in U.S. Pat. No. 5,774,515, which is herein incorporated by references. They are typically large, naturally occurring proteins or carbohydrates, with molecular weights above 100,000 daltons. In vivo, adhesion molecules are typically able to bind to specific cell surface receptors, and mechanically attached cells to the substrate or to adjacent cells. In addition to promoting cell attachment, suitable adhesion molecules can promote other cell responses including cell migration and cell differentiation (which in turn can include the formation of capillary tubes by endothelial cells).


Preferred adhesion molecules include substrate adhesion molecules (SAM's) such as the proteins laminin, fibronectin, collagen, vitronectin, and tenascin, and adhesion peptides or functional synthetic analogs derived from SAM's. Other suitable adhesion molecules include cell-to-cell adhesion molecules (CAM's) such as N-cadherin and P-cadherin.


Parent (i.e., native) adhesion proteins typically have one or more active peptide domains that bind to cell surface receptors and which domains produce the cell attachment, migration, and differentiation effects of the parent adhesion proteins. These domains consist of specific amino acid sequences, several of which have been synthesized and reported to promote the adhesion of endothelial cells. These domains and functional analogs of these domains are termed “adhesion peptides”. In different embodiments, adhesion molecules are adhesion peptides and desirably, adhesion peptides have about 3 to about 30 amino acid residues in their amino acid sequences.


Adhesion peptides from fibronectin include, but are not limited to, RGD (arg-gly-asp) [SEQ ID NO.:1], REDV (arg-glu-asp-val) [SEQ ID NO.:2], and C/H—V (WQPPRARI or trp-gln-pro-pro-arg-ala-arg-ile) [SEQ ID NO.:3]. Adhesion peptides from laminin include, but are not limited to, YIGSR (tyr-ile-gly-ser-arg) [SEQ ID NO.:4] and SIKVAV (ser-ile-lys-val-ala-val) [SEQ ID NO.:5] and F-9 (RYVVLPRPVCFEKGMNYTVR or arg-tyr-val-val-leu-pro-arg-pro-val-cys-phe-glu-lys-gly-met-asn-tyr-thr-val-arg) [SEQ ID NO.:6]. Adhesion peptides from type IV collagen include, but are not limited to, Hep-III (GEFYFDLRLKGDK or gly-glu-phe-tyr-phe-asp-leu-arg-leu-lys-gly-asp-lys) [SEQ ID NO.:7].


While it is believed that nano-craters can selectively promote endothelialization, it is possible that platelet attachment to the nano-cratered surface may also be enhanced, leading to the undesirable effect of clot formation. To minimize any such effect, an anti-thrombotic molecule may be included on the surfaces 102a and 102b of the stent 100 by any suitable means, in amounts sufficient to minimize any platelet attachment during the process of endothelialization.


As used herein, an “anti-thrombotic molecule” is a molecule that reduces or prevents the formation of thrombi or clots on the surface of an implantable device that contacts bodily fluid or tissue, including when implanted in a subject's body. Anti-thrombotic molecules include, without limitation, heparin, and small molecules, such as benzamidine compounds, bicyclic pyrimidine compounds, nitro compounds, thio acid compounds, and proteins and peptides, including tissue-type plaminogen activator (t-PA), protein S and protein C.


The implantable device may be formed entirely from a single material and standard methods know in the art may be used to fashion the device. For example, a mold may be used, and a liquid polymer may be poured into the mold. This methods used will depend on the particular material used and the particular medical device that is to be formed.


In the case of the stent 100, the device may be formed by rolling a sheet or film of material, or by winding a thin strip of material into a helix, as is known in the art. In this way, the nano-craters may be readily formed on each side of the sheet or strip, as discussed below, prior to rolling or winding to form the stent.


The implantable device may also be formed from a substrate material and another material applied to the substrate material to form a bodily fluid or tissue contracting surface by any suitable means, for example, by spin-coating from a solution or suspension, and the nano-craters are subsequently introduced into the surface. This surface layer should have sufficient thickness to introduce nano-craters having depth sufficient to enhance or promote endothelialization.


Without intending to particularly limit the method by which the nano-craters 104 are introduced to the surfaces 102a and 102b of the stent 100, the following illustration of two possible approaches for forming the nano-craters 104 are provided.


The nano-craters 104 may be introduced through controlled degradation of the surfaces 102a and 102b of the stent 100, as depicted in FIG. 2. According to this approach, discrete portions of surfaces 102a and 102b, both of which are formed from a degradable polymer, are etched using a degradative process, for example, by exposing the polymer surface to electron beam radiation or by treating with a chemical that will degrade the surface, for example, strong alkali.


The technique of masking certain areas of the surface 102a and 102b may be employed to define areas of degradation. A higher density material, for example a silicon-based polymer or an acrylic polymer, may be patterned over surface 102a and 102b in which the nano-craters 104 are to be introduced, in a pattern that defines the desired distribution and depth of the nano-craters. For example, a focused ion beam may be used to form the desired pattern in the mask material which is layered on the degradable surface 102a and 102b.


After exposure to the etching means that degrade the unmasked regions of surface 102a and 102b, for example radiation or chemical means, the surface material in the degraded areas may then be leached out using water or solvent in which the degraded portions of the surface material are soluble, but which will not dissolve the non-degraded regions of the surface. The mask material may then be subsequently removed, for example by dissolution in a suitable solvent that dissolves the mask material but not the polymer surface 102a and 102b.


To illustrate, in one example, PLGA, PLLA, PGA, polycaprolactone or polyethylene may be employed to form the stent 100 or surfaces 102a and 102b of the stent 100, both of which degrade in the dry state under electron-beam irradiation.


Thus, the degree of degradation may be controlled using the well-known effects of attenuation with depths of an incident electron beam. The depth of penetration of the incident electron beam is generally proportional to the electron energy or the accelerating voltage being used. This depth-dose distribution is determined by the absorption mechanism of mono-energetic electron beams having electron energy, eV, for a material of density p. The higher the density of a given material, the grater the attenuation effect on the electron beam. This attenuation effect will result in a varying radiation dose across the thickness of the surface and patterned higher density material, resulting in a variation of molecular weight of the polymer across the thickness of the surface.


An example of utilizing an incident electron beam for patterning a surface of a polymeric sample may include use of electron beam lithography, which is typically used in the semiconductor electronics industry for patterning integrated circuits and biosensors. Generally, a polymeric substrate having a radiation-sensitive film or resist may be placed in a vacuum chamber of a scanning-electron microscope and exposed by an electron beam under digital control. Because the beam width may be adjusted to range from a few picometers to several nanometers, an etched pattern may be formed by the beam across the polymer surface.


This variation of molecular weight across the thickness of the surface will result in differing degradation rates at areas masked with the higher density material than those not asked. When these non-masked degraded sections are exposed to water (or another suitable solvent), the leaching of low-molecular weight, water-soluble oligomers from the water-insoluble not-degraded regions of the surface will result in well-defined craters of known lateral dimensions and depth. Thus, the size and shape of the nano-craters 104 may be accurately controlled by this method, for example by controlling the does of the radiation, and the density of the material used to mask, as well as the pattern in which the masking material is applied. This results in a unique surface morphology, as discussed above, that selectively promotes endothelial cell attachment, while not being receptive to platelet attachment.


Alternatively, chemical means can be used with the above-described masking method to produce nano-craters at the surfaces 102a and 102b. For example, sodium hydroxide may be used to dissolve PLA in regions that are not protected by the alkali-resistant mask material, and the dissolved material may then be rinsed away in water to form nano-craters 104. The mask may be removed as described above.


The nano-craters 104 may alternatively be formed on the surfaces 102a and 102b of the stent 100 by including nano-particles that are leachable from the surfaces 102a and 102b.


A “nano-particle” is any granular or particulate material in which the particulates have dimensions in the nano-meter range. The nano-particles may be irregularly shaped, or may be of well-defined size and shape, and may be leached from the surface leaving behind nano-craters corresponding to the size and shape of the nano-particles.


The nano-particles may be formed of any granular or particulate material which can be embedded in the material used to form surface 102a and 102b, which will not dissolve in or become irreversibly bound to the material, and which can then be subsequently leached from the material. For example, the nano-particles can be formed from an inorganic salt, such as sodium chloride, form gelatin, sugar, chitosan, or polyvinyl pyrrolidone.


The nano-particles may be suspended in a dilute solution of a polymer being used to form the implantable device or more preferably, the surface of the implantable device which may then be spin-coated onto the substrate of the device at a desired thickness. The thickness will usually be in the micrometer range. By casting a very thin layer containing the nano-particles, it is possible to form a layer of polymer on an implantable device that has nano-craters only at the surface.


Subsequently, these particles on the surface are either leached out upon exposure to water or another suitable solvent, or are eroded once the device comes in contact with bodily fluid or tissue, for example when stent 100 is implanted, leaving behind a surface with well defined nano-craters 104 of know dimensions. Advantageously, the dimensions of the nano-craters 104 may be varied by varying the size and shape of the nano-particles dispersed in the polymer.


If the bodily fluid-contacting or tissue-contacting surface of the implantable device is to contain adhesion-promoting molecules, the nano-craters may be created, for example by irradiation, and concurrently the surface may be modified to release adhesion-promoting molecules and/or growth-stimulating molecules, for example into a lumen or cavity of the implantable device. The adhesion-promoting molecules and/or growth-stimulating molecules may be passed to a polymer used to form the implantable device or the surface of the implantable device prior to coating the polymer on the substrate of the implantable device, and forming nano-craters.


However, adhesion-promoting molecules and growth-stimulating molecules may typically be proteins, which are sensitive biomolecules that may be denatured by addition to a liquid polymer, or when subjected to high intensity radiation. Thus, the adhesion-promoting molecules and/or growth-stimulating molecules may first be encapsulated in nano-particles of well-defined size and shape as it known in the art, for example, as described in U.S. Pat. No. 6,589,562 which is herein fully incorporated by reference. The nano-particles may be leached out as discussed above, leaving behind the nano-craters and simultaneously releasing the adhesion-promoting molecules and/or growth-stimulating molecules, for example into a lumen. The nano-particles, when containing adhesion-promoting molecules and/or growth-stimulating molecules for delivery to bodily fluid or tissue comprise a material that is soluble in bodily fluid or tissue, for example, gelatin.


An anti-thrombotic molecule may be included in the nano-crated surface of an implantable device in a similar manner.


In an alternative embodiment, an implantable device with reduced thrombogenicity is achieved by providing the device with a surface that will degrade in a layered fashion when it contacts bodily fluid or tissue. This embodiment is useful for applications in which the device will be in contact with bodily fluid or tissue for a relatively short period of time, for example, a catheter or dialysis tubing that is in such contact for less than 24 hours. Preferably, the layers degrade relatively quickly, so as to prevent the formation of thrombi. This means that the degradation time for a given layer upon contacting bodily fluid or tissue may be, for example, between about 5 minutes and about 1 hour.


Thus, with reference to FIG. 3, in an illustrative embodiment, a stent 100′ has first degradable layers 106a and 106b disposed about a central core 110, and which layers provide surfaces 102a and 102b that comes into contact with bodily fluid or tissue, including blood, and second degradable layers 108a and 108b, between layers 106a and 106b, respectively, and the central core 110 of stent 100′. In the depicted embodiment, the stent 100′ has a first surface 102a, which forms the exterior surface of the stent and an interior surface 102b which defines the lumen of the stent.


The second degradable layers 108a and 108b are the inner layer relative to the outer surfaces 102a′ and 102b, respectively, and have a slower degradation rate than the first degradable layers 106a and 106b. Therefore, on contact with bodily fluid or tissue, there is a peeling effect resulting from successive degradation of first degradable layers 106a and 106b followed by degradation of the second degradable layers 108a and 108b, and any thrombus formation on surface 102a and 102b is removed as the layers erode.


As mentioned above, the stent 100′ may also be configured and comprised in the manner as shown and described in U.S. patent application Ser. No. 10/867,617, which has been incorporated above by reference in its entirety. In one variation, the stent 100′ configured as disclosed in U.S. patent application Ser. No. 10/867,617 may comprise the central core 110 having the multiple degradable layers disposed thereon. In other variations, it may be possible to have the multiple degradable layers correspond to the multiple layers comprising the stent structure.


The degradable layers 106a and 106b and 108a and 108b may be formed from any biodegradable polymers that are generally known in the art and described above and hereafter. For example, suitable polymers include polylactic acid (PLA) and polyglycolic acid (PGA) and copolymers of PLA and PGA (PLGA). These polymers may be amorphous or semi-crystalline.


For example, in one embodiment layers 106a and 106b may comprise PLA and the layers 108a and 108b may comprise PLGA, particularly PLDA 80/20; PLGA 75/25; or PLGA 53/47, wherein the numbers in the copolymer represent the percentage of PLA and PGA by weight, respectively, included in the copolymer.


Preferably, the thickness of each layers 106a and 106b and 108a and 108b is in the micrometer or sub-micrometer range, for example about 0.5 μm to about 10 μm.


In stent 100′, the central core 110 may comprise a different material than layers 106a, 106b, 108a and 108b, and the material comprising the respective layers may be applied to central core 110. Alternatively, stent 100′ may be formed of a single polymeric material but having first and second degradable layers of different average molecular weights of the polymer than found in central core 110, so as to form the discrete layer 106a, 106b, 108a, and 108b about central core 110, as described below.


Without intending to particularly limit the method by which the degradable layers 106a and 106b and 108a and 108b having varying degradation rates are provided on the central core 110, the following illustration of two possible approaches for forming the degradable layers are provided.


Polymers having different degradation rates can be selected and applied successively such that the layers 108a and 108b comprise a polymer with a slower degradation rate. A polymer with a faster degradation rate is selected for layers 106a and 106b such that layer 106a and 106b degrade more rapidly and remove any thrombus that may have formed on the surfaces 102a and 102b, respectively.


A skilled person will appreciate that a layered device having first and second degradable layers may comprise additional degradable layers, and that the degradation rate of each degradable layer increases with each successively inward layer such that the outer-most layer degrades more quickly and that the inner-most layer degrades most slowly. For example, in one particular embodiment, a layered device may comprise the following layers disposed about a central core: PLA; PLGA 80/20; PLGA 75/25; and PLGA 53/47 in the given order with PLGA 53/47 being the outer-most layer.


The suitable number of layers to be applied can be readily determined and will depend on the degradation rates of the layers and the particular type of device and its intended use, including the intended duration of contact with bodily fluid or tissue.


Each of such layers may be spin-coated or solvent cast on to a substrate material forming the implantable device, using a solution or suspension containing, for example, about 10 to about 40% polymer by weight. As will be appreciated, other suitable means of applying thin layers of a polymer to a substrate may also be employed, for example, vapour deposition.


Alternatively, controlled degradation of a surface of an implantable device may be effected, for example, using radiation such as electron beam radiation. This method utilizes the attenuation effect of electron beam radiation within an irradiated material.


To illustrate, a single biodegradable material may be applied to the surface of an implantable device as described above and then irradiated to provide layers having different average molecular weights of the biodegradable material, and therefore varying degradation rates.


The suitable thickness of the material to be applied will typically be in the micrometer range, for example about 1 micron to about 20 microns, and can be readily determined. The desired thickness will depend on the particular polymer used and on the particular type of device and its intended use, including the intended duration of contact with bodily fluid and tissue.


The mechanism of attenuation, as discussed above, can be described as the loss of energy of the accelerating electrons. The depth of penetration is proportional to the electron energy or the accelerating voltage, and is attenuated in a manner proportional to the density of the material being penetrated. This attenuation effect will result in a varying radiation does through the depth of the material as the beam is attenuated as it travels deeper into the material, with the exterior surface receiving the strongest does of radiation. This will result in a variation of molecular weight in the surface material as a function of penetration depth or material thickness. This variation of molecular weight through the depth of the material will in turn result in different degradation rates of the material coated on the device, thereby providing the first degradable layer, which due to the higher radiation does will have a lower molecular weight and will degrade faster then the underlying second degradable layer. This will result in a ‘layer peeling’ effect across the thickness of the polymer when in contact with bodily fluid or tissue.


The above-described devices can provide an implantable device having reduced thrombogenicity on contact with bodily fluid or tissue, for example when implanted, as compared to that typically observed with implantable medical devices. Standard surgical methods for implanting medical devices are known in the art. The method of implantation and duration of implantation will depend on the type of implantable device used, for example, a stent or a valve, the purpose of implantation and the disorder or condition that is to be treated with the implantable medical device. Thus, a method for reducing thrombogenicity, and for enhancing or promoting endothelialization, of an implantable device having at least one surface for contacting bodily fluid or tissue is contemplated.


The method comprises providing on the at least one surface a plurality of nano-craters that enhance or promote endothelialization of the at least one surface.


Alternatively the method comprises providing at least one first degradable layer which provides said at least one surface and which is disposed about a central core, and at least one second degradable layer between said first degradable layer and the central core, wherein said first degradable layer has a first degradation rate and said second degradable layer has a second degradation rate such that said at least one first degradable layer degrades more rapidly then said at least one second degradable layer so as to remove any thrombus that may be formed on said at least one surface.


All documents referred to herein are fully incorporated by reference.


Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of know equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. All technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art of this invention, unless defined otherwise.


Example 1

For the following examples, each polymer was first dissolved in chloroform. Nano-sized salt particles were ground and sieved, and then dispersed in the polymer solution with constant stirring until the particles were visually uniformly dispersed. The polymer concentration was chosen such that it had sufficiently high viscosity to maintain a stable dispersion. The dispersion was then cast as a film of required thickness using a coater. The film was dried in an oven at 37° C., and then left at room temperature for several days in a dry environment. The dried films were immersed in water for 14 days, with constant exchange of the water. The salt nano-particles were thus leached out, and the resulting film was dried again at 37° C. and at room temperature.


Control films were prepared as pure polymer films without any surface modification.


PLLA and PLGL films having nano-craters in the surface were obtained by leaching out incorporated nano-particles of NaCl, as indicated in Table 1.


The best result were obtained with PLLA polymer surfaces prepared by incorporation and leaching out of salt particles (<90 Micron Diameter). Rapid endothelial cell attachment was seen with these surfaces, with significant coverage of the surface by cells.


Although early attachment of cells to the PLGA polymer film was observed, the results obtained with PLGA did not result in significant endothelialization of the polymer film. This is likely due to the molecular weight of PLGA chosen, or the ratio of lactide to glycolide in the copolymer, resulting in a polymer that degraded under the conditions used to leach the salt particles, and confirms that the degradation properties of the polymer and dissolution rate of the leachable salt particle can affect the formation of nano-craters. The resulting craters were therefore likely too large and improperly formed to promote confluent growth and attachment of the cells. This problem can be solved by varying the PLGA used to select a more stable form of PLGA and to increase the rate of leaching of salt particles, such that the PLGA is not degraded during the leaching process.









TABLE 1







Results of Endothelialization of Nano-Cratered Surfaces.
















First







endothrlial




Sample
Surface
Cell Seeding
call
Result at days


Material
Preparation
Treatment
(cells/sq cm)
attachment
4/5





Control PLLA
Polymer +
NIL
20000
36 hours
Day 5



Solvent PLLA



approximately







20%







confluency


Contold
Polymer +
NIL
As Above
36 hours
Day 5


PLGA
Solvent PLGA



approximately



80:20



40%







confluency


PLLA with
Polymer +
Leached NaCl
As Above
2 hours
At Day 4


Nanocraters
Solvent PLLA
99% purity


about 70%




<90 Microns


confluency




1%


Seen.




concentration







Leaching







period 15







days.





PLGA with
Polymer +
Leached NaCl
As Above
6 hours
At Day 4


nanocraters
Solvent PLGA
990% Purity


about 5%



80:20
<90 microns


confluency




1%


Seen.




concentration







Leaching







period 15







days.









Example 2

In another example of a method for modifying a surface of a polymer for implantation within a patient body, porogen leaching of surfaces may be utilized to yield a surface which enhances endothelial cell growth over a defined range of surface features. In this particular example, surface pores were created by filling polymers such as Poly caprolactone (PCL), Poly L-lactide (PLLA), Poly (lactide-co-glycolide), etc. (although any of the other suitable polymers described herein may be utilized) with leaching agents of sugar and gelatin.


The sugar and gelatin particles ranged in size from 20 to 90 microns in diameter (although particles as small as 5 microns may also be utilized) where the average particle sizes typically ranged from 20, 45, and 90 microns. The leaching agents were added in concentrations ranging from 1 to 10% by weight in the polymer. More particularly, the leaching agents were added in concentrations ranging from 1%, 5%, and 10% by weight in the polymer.


The leaching agents were then leached out with water from the polymer for a period of 10 to 12 days and the surface porosity was characterized by a scanning electron microscope (SEM) for crater dimensions and inter-crater spacing. With the physical characteristics determined, the surfaces of the polymer were then exposed to endothelial cells over an 11 day period, at the end of which the cells attached to the surface were counted and correlated to the surface features.



FIG. 4 illustrates some of the results of the number of cells correlated to pore size in a PLLA polymer sample at day 9, which is representative of the results. FIG. 5 also illustrates some of the results of the number of cells correlated to pore size in a PLGA polymer sample (specifically PLGA 80/20) also at day 9. In both the PLLA and PLGA polymers, each sample was prepared utilizing the methods described above. Generally, endothelial cell growth appeared better on PLGA 80/20 samples than on PLLA samples. Moreover, both gelatin and sugar pyrogens appear to act similarly and regardless of the porogen used, cell growth appears inversely dependent on pore size. However, gelatin appeared to be optimal for use as a porogen in the size range of about 5 to 40 microns at concentrations of about 5 to 10% in the starting solution. The PCL samples, also prepared as described above, showed growth of endothelial cells although the growth did not appear dependent on pore size in the range studied.


Generally, endothelial cell attachment and proliferation is higher at lower crater sizes (between about 5-10 microns) and decreases with higher crater size up to about 90 microns; however, compared to controls (no craters), all the samples showed enhanced endothelial cell attachment.


By changing the concentration of the particles in the polymer (prior to leaching), mentioned above as 1%, 5%, and 10% concentrations, the inter-pore distances along the polymer surfaces were varied from an average of about 50 microns to 250 microns. As illustrated by the results in FIG. 6, an inter-pore distance ranging from about 50 to 100 microns and more preferably between 50 to 80 microns appeared optimal for attachment and growth of the endothelial cells.


Accordingly, endothelial cell growth appears to correlate inversely to pore size on surfaces of PLLA and PLGA samples, but not to PCL samples. As pore size is decreased (e.g., down to about 5 to 10 microns), endothelial cell growth is increased. However, at all pore sizes, PCL showed good endothelial cell growth on its surface.


Example 3

As mentioned above, chemicals such as sodium hydroxide may be used to dissolve PLA in regions unprotected by an alkali-resistant mask material where the dissolved material may be rinsed away in water to form nano-craters. In another example, the polymer surface may be first irradiated prior to etching with the sodium hydroxide to enhance the etching process.


In this example, samples of PLGA, PCL, and PLLA (other suitable polymers described above may alternatively be utilized) were first irradiated with an electron beam and then etched using the sodium hydroxide, as described above, for a period of 16 hours to create surface features. The average surface roughness of the samples was measured using an atomic force microscope (AFM) and the etched samples were then exposed to endothelial cells. Growth was quantified over a period of 15 days and the irradiated and etched samples were compared to control samples after 4 days, 8 days, and 15 days. Table 2 shows a comparison of the results for sample roughness between the irradiated and control samples where the MTS value is an indication of the number of active cells.









TABLE 2







Results of Comparison For Irradiated and Control Samples With Respect to


Sample Roughness and Cell Growth.













AFM Avg surface

MTS Average
MTS Average
MTS Average



Roughness (Scan

Absorbance after 4
Absorbance after 8
Absorbance after 15



Size 50 μm)
Static Contact Angle
days
days
days





PLGA Control
 3.3 ± 1
7.32 ± 1
0.51
0.37
0.26


PLGA Modified
 93 ± 3
57.4 ± 2
0.57
0.29
0.45


PLLA Control
646 ± 9
94.2 ± 2
0.40
0.29
0.40


PLLA Modified
 333 ± 27
63.4 ± 1
0.51
0.17
0.27


PCL Control
 259 ± 20
80.2 ± 3
0.39
0.24
0.28


PCL Modified
 390 ± 16
61.8 ± 1
0.53
0.38
0.39





*Modified = Ebeam with 2.5 Mrads + 16 hours 0.1N NaOH immersion






Generally, irradiating samples prior to etching with sodium hydroxide gives surface features that are rougher than control samples. Table 3 shows a comparison of the results for the irradiated and control samples with respect to live cell growth and total cell growth.









TABLE 3







Results of Comparison For Irradiated and Control Samples With Respect to


Live Cell Growth and Total Cell Growth.














Hemocytometer
Hemocytometer
Hemocytometer
Hemocytometer
Hemocytometer
Hemocytometer



Avg Live Cells
Avg total Cells
Avg Live Cells
Avg total Cells
Avg Live Cells
Avg total Cells



Count after 4 day
Count after 4 day
Count after 8 day
Count after 8 day
Count after 15 day
Count after 15 day
















PLGA Control
5400
9600
9300
15800
9400
22700


PLGA Modified
8800
12800
9700
17800
17800
31400


PLLA Control
5300
9000
3800
4900
13500
27700


PLLA Modified
6500
8800
3300
4800
13600
27400


PCL Control
4400
9200
1530
3800
3060
12000


PCL Modified
4100
7600
9830
14200
5300
23400





*Modified = Ebeam with 2.5 Mrads + 16 hours 0.1N NaOH immersion






Generally, the surface-modified samples show enhanced endothelial cell growth for PLGA and PCL samples except for PLLA samples. The endothelial cell growth also appeared to correlate well with overall surface roughness of PLGA and PCL samples where endothelial cell growth increases as surface roughness increases.


As can be understood by one skilled in the art, many modifications to the exemplary embodiments described herein are possible. The invention, rather, is intended to encompass all such modification within its scope, as defined by the claims.

Claims
  • 1. An implantable device comprising: a central core defining a lumen through said core with an inner core surface along said lumen and an outer core surface;at least one first degradable layer formed upon said inner core surface and said outer core surface for contacting bodily fluid or tissue, wherein the first degradable layer comprises a polymer selected from the group consisting of PLGA 80/20, PLGA 75/25, and PLGA 53/47; andat least one second degradable layer formed between said inner core surface and said first degradable layer and also between said outer core surface and said first degradable layer, wherein said first degradable layer has a first degradation rate and said second degradable layer has a second degradation rate such that said at least one first degradable layer degrades more rapidly than said at least one second degradable layer on contact with bodily fluid or tissue.
  • 2. The implantable device of claim 1, wherein the first degradable layer comprises a different material from the second degradable layer.
  • 3. The implantable device of claim 1, wherein the second degradable layer comprises poly-lactide (PLA) and the first degradable layer comprises poly(lactide-co-glycolide) (PLGA).
  • 4. The implantable device of claim 1, further comprising: at least one third degradable layer between the at least one second degradable layer and the central core and having a third degradation rate slower than the second degradation rate; andat least one fourth degradable layer between the at least one third degradable layer and the central core and having a fourth degradation rate slower than the third degradation rate.
  • 5. The implantable device of claim 4, wherein the first degradable layer comprises PLGA 53/47, the second degradable layer comprises PLGA 75/25, the third degradable layer comprises PLGA 80/20, and the fourth degradable layer comprises PLA.
  • 6. The implantable device of claim 1, wherein the implantable device is selected from the group consisting of a stent, a graft, a conduit, a valve, and a dialysis tubing.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority to U.S. Provisional Patent Application No. 60/808,558, filed May 26, 2006; this application is also a continuation-in-part of U.S. Non-provisional patent application Ser. No. 10/867,617, filed Jun. 15, 2004 (now abandoned). The disclosure of all priority applications is incorporated herein by reference in their entirety.

US Referenced Citations (469)
Number Name Date Kind
4173689 Lyman et al. Nov 1979 A
4334327 Lyman et al. Jun 1982 A
4655771 Wallsten Apr 1987 A
4661530 Gogolewski et al. Apr 1987 A
4733665 Palmaz Mar 1988 A
4739762 Palmaz Apr 1988 A
4770664 Gogolewski Sep 1988 A
4776337 Palmaz Oct 1988 A
4834747 Gogolewski May 1989 A
4950258 Kawai et al. Aug 1990 A
4955899 Della Corna et al. Sep 1990 A
5061275 Wallsten et al. Oct 1991 A
5102417 Palmaz Apr 1992 A
5104400 Berguer et al. Apr 1992 A
5139480 Hickle et al. Aug 1992 A
5152782 Kowligi et al. Oct 1992 A
5163952 Froix Nov 1992 A
5258020 Froix Nov 1993 A
5288711 Mitchell et al. Feb 1994 A
5383887 Nadal Jan 1995 A
5421955 Lau et al. Jun 1995 A
5443458 Eury Aug 1995 A
5449373 Pinchasik et al. Sep 1995 A
5514154 Lau et al. May 1996 A
5516781 Morris et al. May 1996 A
5563146 Morris et al. Oct 1996 A
5607467 Froix Mar 1997 A
5630162 Wilkinson et al. May 1997 A
5630840 Mayer May 1997 A
5645559 Hachtman et al. Jul 1997 A
5665728 Morris et al. Sep 1997 A
5670161 Healy et al. Sep 1997 A
5716410 Wang et al. Feb 1998 A
5733303 Israel et al. Mar 1998 A
5741323 Pathak et al. Apr 1998 A
5744515 Clapper Apr 1998 A
5769816 Barbut et al. Jun 1998 A
5795318 Wang et al. Aug 1998 A
RE35988 Winston et al. Dec 1998 E
5843089 Sahatjian et al. Dec 1998 A
5843120 Israel et al. Dec 1998 A
5848987 Baudino et al. Dec 1998 A
5922021 Jang Jul 1999 A
5935164 Iversen Aug 1999 A
5935506 Schmitz et al. Aug 1999 A
5954744 Phan et al. Sep 1999 A
5962004 Jannetta Oct 1999 A
5962007 Cooper et al. Oct 1999 A
5964744 Balbierz et al. Oct 1999 A
5972018 Israel et al. Oct 1999 A
5980552 Pinchasik et al. Nov 1999 A
5980555 Barbut et al. Nov 1999 A
5989281 Barbut et al. Nov 1999 A
6007573 Wallace et al. Dec 1999 A
6059811 Pinchasik et al. May 2000 A
6066167 Lau et al. May 2000 A
6086605 Barbut et al. Jul 2000 A
6090097 Barbut et al. Jul 2000 A
6090134 Tu et al. Jul 2000 A
6117154 Barbut et al. Sep 2000 A
6117168 Yang et al. Sep 2000 A
6136016 Barbut et al. Oct 2000 A
6153252 Hossainy et al. Nov 2000 A
6160084 Langer et al. Dec 2000 A
6168619 Dinh et al. Jan 2001 B1
6217815 Sisbarro Apr 2001 B1
6224627 Armstrong et al. May 2001 B1
6231326 Sisbarro May 2001 B1
6231544 Tsugita et al. May 2001 B1
6235045 Barbut et al. May 2001 B1
6248129 Froix Jun 2001 B1
6254632 Wu et al. Jul 2001 B1
6267776 O'Connell Jul 2001 B1
6273901 Whitcher et al. Aug 2001 B1
6281262 Shikinami Aug 2001 B1
6309412 Lau et al. Oct 2001 B1
6309414 Rolando et al. Oct 2001 B1
6315792 Armstrong et al. Nov 2001 B1
6322847 Zhong et al. Nov 2001 B1
6331188 Lau et al. Dec 2001 B1
6338739 Datta et al. Jan 2002 B1
6338793 Putman Jan 2002 B1
6364904 Smith Apr 2002 B1
6379383 Palmaz et al. Apr 2002 B1
6423086 Barbut et al. Jul 2002 B1
6423092 Datta et al. Jul 2002 B2
6432133 Lau et al. Aug 2002 B1
6443982 Israel et al. Sep 2002 B1
6461381 Israel et al. Oct 2002 B2
6464722 Israel et al. Oct 2002 B2
6485511 Lau et al. Nov 2002 B2
6500204 Igaki Dec 2002 B1
6503270 Richter et al. Jan 2003 B1
6508834 Pinchasik et al. Jan 2003 B1
6517559 O'Connell Feb 2003 B1
6520986 Martin et al. Feb 2003 B2
6530950 Alvarado et al. Mar 2003 B1
6533805 Jervis Mar 2003 B1
6533808 Thompson Mar 2003 B1
6537295 Petersen Mar 2003 B2
6537311 Cox et al. Mar 2003 B1
6537312 Datta et al. Mar 2003 B2
6540774 Cox Apr 2003 B1
6540775 Fischell et al. Apr 2003 B1
6540776 Sanders Millare et al. Apr 2003 B2
6540779 Richter et al. Apr 2003 B2
6544279 Hopkins et al. Apr 2003 B1
6547815 Myers Apr 2003 B2
6547817 Fischell et al. Apr 2003 B1
6551350 Thornton et al. Apr 2003 B1
6554758 Turnlund et al. Apr 2003 B2
6554858 Dereume et al. Apr 2003 B2
6562063 Euteneuer et al. May 2003 B1
6562065 Shanley May 2003 B1
6565596 White et al. May 2003 B1
6565598 Lootz May 2003 B1
6565600 Hojeibane May 2003 B2
6565602 Rolando et al. May 2003 B2
6575887 Schrayer Jun 2003 B1
6575994 Marin et al. Jun 2003 B1
6579306 Voelker et al. Jun 2003 B1
6579308 Jansen et al. Jun 2003 B1
6579310 Cox et al. Jun 2003 B1
6582447 Patel et al. Jun 2003 B1
6582458 White et al. Jun 2003 B1
6582467 Teitelbaum et al. Jun 2003 B1
6585747 Limon et al. Jul 2003 B1
6585757 Callol Jul 2003 B1
6589264 Barbut et al. Jul 2003 B1
6589266 Whitcher et al. Jul 2003 B2
6589276 Pinchasik et al. Jul 2003 B2
6589562 Shefer et al. Jul 2003 B1
6592546 Barbut et al. Jul 2003 B1
6592617 Thompson Jul 2003 B2
6596021 Lootz Jul 2003 B1
6596022 Lau et al. Jul 2003 B2
6599308 Amplatz Jul 2003 B2
6602279 Nicholas Aug 2003 B1
6605107 Klein Aug 2003 B1
6605110 Harrison Aug 2003 B2
6605113 Wilk Aug 2003 B2
6607501 Gorsuch Aug 2003 B2
6607553 Healy et al. Aug 2003 B1
6613073 White et al. Sep 2003 B1
6616690 Rolando et al. Sep 2003 B2
6623521 Steinke et al. Sep 2003 B2
6626933 Lau et al. Sep 2003 B1
6626934 Blaeser et al. Sep 2003 B2
6626938 Butaric et al. Sep 2003 B1
6626939 Burnside et al. Sep 2003 B1
6629991 Lau et al. Oct 2003 B1
6635082 Hossainy et al. Oct 2003 B1
6635084 Israel et al. Oct 2003 B2
6652558 Patel et al. Nov 2003 B2
6652572 Kugler et al. Nov 2003 B2
6652574 Jayaraman Nov 2003 B1
6652575 Wang Nov 2003 B2
6652579 Cox et al. Nov 2003 B1
6652581 Ding Nov 2003 B1
6653426 Alvarado et al. Nov 2003 B2
6656219 Wiktor Dec 2003 B1
6656220 Gomez et al. Dec 2003 B1
6666883 Seguin et al. Dec 2003 B1
6669722 Chen et al. Dec 2003 B2
D484979 Fontaine Jan 2004 S
6673106 Mitelberg et al. Jan 2004 B2
6679910 Granada Jan 2004 B1
6679911 Burgermeister Jan 2004 B2
6685736 White et al. Feb 2004 B1
6687553 Erickson et al. Feb 2004 B2
6689158 White et al. Feb 2004 B1
6689159 Lau et al. Feb 2004 B2
6699256 Logan et al. Mar 2004 B1
6699276 Sogard et al. Mar 2004 B2
6699278 Fischell et al. Mar 2004 B2
6702844 Lazarus Mar 2004 B1
6702846 Mikus et al. Mar 2004 B2
6702850 Byun et al. Mar 2004 B1
6706062 Vardi et al. Mar 2004 B2
6709425 Gambale et al. Mar 2004 B2
6709453 Pinchasik et al. Mar 2004 B2
6709454 Cox et al. Mar 2004 B1
6716240 Fischell et al. Apr 2004 B2
6719782 Chuter Apr 2004 B1
6719934 Stinson Apr 2004 B2
6736842 Healy et al. May 2004 B2
6740114 Burgermeister May 2004 B2
6746476 Hojeibane Jun 2004 B1
6752829 Kocur et al. Jun 2004 B2
6753071 Pacetti Jun 2004 B1
6756094 Wang et al. Jun 2004 B1
6758858 McCrea et al. Jul 2004 B2
6758859 Dang et al. Jul 2004 B1
6758860 Penn et al. Jul 2004 B1
6764506 Roubin et al. Jul 2004 B2
6764507 Shanley et al. Jul 2004 B2
6770088 Jang Aug 2004 B1
6770089 Hong et al. Aug 2004 B1
6770091 Richter et al. Aug 2004 B2
6773455 Allen et al. Aug 2004 B2
6776022 Kula et al. Aug 2004 B2
6780164 Bergheim et al. Aug 2004 B2
6783543 Jang Aug 2004 B2
6783544 Lynch et al. Aug 2004 B2
6786929 Gambale et al. Sep 2004 B2
6790226 Edwin et al. Sep 2004 B2
6790227 Burgermeister Sep 2004 B2
6790228 Hossainy et al. Sep 2004 B2
6792979 Konya et al. Sep 2004 B2
6793672 Khosravi et al. Sep 2004 B2
6794485 Shalaby et al. Sep 2004 B2
6796997 Penn et al. Sep 2004 B1
6796999 Pinchasik Sep 2004 B2
6802858 Gambale et al. Oct 2004 B2
6805705 Hong et al. Oct 2004 B2
6805706 Solovay et al. Oct 2004 B2
6805898 Wu et al. Oct 2004 B1
6808533 Goodwin et al. Oct 2004 B1
6814746 Thompson et al. Nov 2004 B2
6814748 Baker et al. Nov 2004 B1
6814749 Cox et al. Nov 2004 B2
6818013 Mitelberg et al. Nov 2004 B2
6818014 Brown et al. Nov 2004 B2
6818015 Hankh et al. Nov 2004 B2
6833153 Roorda et al. Dec 2004 B1
6835203 Vardi et al. Dec 2004 B1
6846323 Yip et al. Jan 2005 B2
6849086 Cragg Feb 2005 B2
6855125 Shanley Feb 2005 B2
6855162 Parodi Feb 2005 B2
6858037 Penn et al. Feb 2005 B2
6860898 Stack et al. Mar 2005 B2
6860901 Baker et al. Mar 2005 B1
6860946 Hossainy et al. Mar 2005 B2
6863685 Davila et al. Mar 2005 B2
6866805 Hong et al. Mar 2005 B2
6875228 Pinchasik et al. Apr 2005 B2
6875229 Wilson et al. Apr 2005 B2
6881223 Penn et al. Apr 2005 B2
6884258 Vardi et al. Apr 2005 B2
6887264 Penn et al. May 2005 B2
6890350 Walak May 2005 B1
6893458 Cox et al. May 2005 B2
6896697 Yip et al. May 2005 B1
6896699 Wilson et al. May 2005 B2
6899729 Cox et al. May 2005 B1
6908479 Lau et al. Jun 2005 B2
6908624 Hossainy et al. Jun 2005 B2
6913619 Brown et al. Jul 2005 B2
6920882 Berg et al. Jul 2005 B2
6923828 Wiktor Aug 2005 B1
6932832 Patel et al. Aug 2005 B2
6932930 DeSimone et al. Aug 2005 B2
6935404 Duerig et al. Aug 2005 B2
6939371 Kugler et al. Sep 2005 B2
6942689 Majercak Sep 2005 B2
6945949 Wilk Sep 2005 B2
6949117 Gambale et al. Sep 2005 B2
6955686 Majercak et al. Oct 2005 B2
6955687 Richter et al. Oct 2005 B2
6955688 Wilson et al. Oct 2005 B2
6960219 Grudem et al. Nov 2005 B2
6960228 Mitelberg et al. Nov 2005 B2
6962603 Brown et al. Nov 2005 B1
6981985 Brown et al. Jan 2006 B2
6981986 Brown et al. Jan 2006 B1
6989071 Kocur et al. Jan 2006 B2
6991642 Petersen Jan 2006 B2
6991647 Jadhav Jan 2006 B2
6997948 Stinson Feb 2006 B2
6997949 Tuch Feb 2006 B2
7001419 DiCaprio et al. Feb 2006 B2
7001424 Patel et al. Feb 2006 B2
7004966 Edwin et al. Feb 2006 B2
D516723 Shanley Mar 2006 S
7008446 Amis et al. Mar 2006 B1
7008466 Collins Mar 2006 B2
7011672 Barbut et al. Mar 2006 B2
7018401 Hyodoh et al. Mar 2006 B1
7029492 Mitsudou et al. Apr 2006 B1
7029493 Majercak et al. Apr 2006 B2
7037331 Mitelberg et al. May 2006 B2
7048014 Hyodoh et al. May 2006 B2
7052513 Thompson May 2006 B2
D523558 Shanley Jun 2006 S
7060088 Fischell et al. Jun 2006 B1
7060089 Ley et al. Jun 2006 B2
7063719 Jansen et al. Jun 2006 B2
RE39157 Hess Jul 2006 E
7070617 Kula et al. Jul 2006 B2
7081130 Jang Jul 2006 B2
7087078 Hildebrand et al. Aug 2006 B2
7094255 Penn et al. Aug 2006 B2
7097652 Becker et al. Aug 2006 B2
7100617 Maginot Sep 2006 B1
7101392 Heath Sep 2006 B2
7105019 Hojeibane Sep 2006 B2
7112298 Kampa et al. Sep 2006 B2
7118593 Davidson et al. Oct 2006 B2
7122049 Banas et al. Oct 2006 B2
7135039 De Scheerder et al. Nov 2006 B2
7137993 Acosta et al. Nov 2006 B2
7141062 Pinchasik et al. Nov 2006 B1
7147649 Thomas Dec 2006 B2
7160592 Rypacek et al. Jan 2007 B2
7166125 Baker et al. Jan 2007 B1
7169170 Widenhouse Jan 2007 B2
7169173 Hossainy et al. Jan 2007 B2
7169174 Fischell et al. Jan 2007 B2
7169177 Obara Jan 2007 B2
7172623 Hansen et al. Feb 2007 B2
7175654 Bonsignore et al. Feb 2007 B2
7179286 Lenz Feb 2007 B2
7179288 Shanley Feb 2007 B2
7195648 Jones et al. Mar 2007 B2
7204847 Gambale Apr 2007 B1
7204848 Brown et al. Apr 2007 B1
7208010 Shanley et al. Apr 2007 B2
7208011 Shanley et al. Apr 2007 B2
7214240 Bonsignore et al. May 2007 B2
7220275 Davidson et al. May 2007 B2
7226558 Nieman et al. Jun 2007 B2
7232421 Gambale et al. Jun 2007 B1
7252679 Fischell et al. Aug 2007 B2
7252680 Freitag Aug 2007 B2
7258697 Cox et al. Aug 2007 B1
7264633 Bonsignore Sep 2007 B2
7270668 Andreas et al. Sep 2007 B2
7288111 Holloway et al. Oct 2007 B1
7291166 Cheng et al. Nov 2007 B2
7294146 Chew et al. Nov 2007 B2
7294214 Craig Nov 2007 B2
7300456 Andreas et al. Nov 2007 B2
7311726 Mitelberg et al. Dec 2007 B2
7311727 Mazumder et al. Dec 2007 B2
7316710 Cheng et al. Jan 2008 B1
7316711 Allen et al. Jan 2008 B2
7320702 Hammersmark et al. Jan 2008 B2
7323007 Sano Jan 2008 B2
7326241 Jang Feb 2008 B2
7326245 Rosenthal et al. Feb 2008 B2
7329366 Gale et al. Feb 2008 B1
7331984 Tu et al. Feb 2008 B2
7338519 Fischell et al. Mar 2008 B2
7341598 Davidson et al. Mar 2008 B2
7347867 Phelps et al. Mar 2008 B2
7357813 Burgermeister Apr 2008 B2
7572287 Stinson Aug 2009 B2
7618448 Schmitz et al. Nov 2009 B2
8206635 Ramzipoor et al. Jun 2012 B2
8206636 Ramzipoor et al. Jun 2012 B2
20010014717 Hossainy et al. Aug 2001 A1
20010029398 Jadhav Oct 2001 A1
20010039432 Whitcher et al. Nov 2001 A1
20020019661 Datta et al. Feb 2002 A1
20020062134 Barbut et al. May 2002 A1
20020077596 McKenzie et al. Jun 2002 A1
20020077693 Barclay et al. Jun 2002 A1
20020082682 Barclay et al. Jun 2002 A1
20020143388 Datta et al. Oct 2002 A1
20020165601 Clerc Nov 2002 A1
20020169601 Nishio Nov 2002 A1
20020188240 Gorsuch Dec 2002 A1
20020193864 Khosravi et al. Dec 2002 A1
20030031699 Van Antwerp Feb 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030045924 Datta et al. Mar 2003 A1
20030050678 Sierra et al. Mar 2003 A1
20030050687 Schwade et al. Mar 2003 A1
20030060836 Wang et al. Mar 2003 A1
20030069629 Jadhav et al. Apr 2003 A1
20030139765 Patel et al. Jul 2003 A1
20030144730 Datta et al. Jul 2003 A1
20030149475 Hyodoh et al. Aug 2003 A1
20030153945 Patel et al. Aug 2003 A1
20030157241 Hossainy et al. Aug 2003 A1
20030163159 Patel et al. Aug 2003 A1
20030176888 O'Connell Sep 2003 A1
20030195628 Bao et al. Oct 2003 A1
20030199918 Patel et al. Oct 2003 A1
20030208227 Thomas Nov 2003 A1
20030208259 Penhasi Nov 2003 A1
20030216804 DeBeer et al. Nov 2003 A1
20030225447 Majercak et al. Dec 2003 A1
20040015187 Lendlein et al. Jan 2004 A1
20040030377 Dubson et al. Feb 2004 A1
20040033251 Sparer et al. Feb 2004 A1
20040034403 Schmitt Feb 2004 A1
20040034405 Dickson Feb 2004 A1
20040047909 Ragheb et al. Mar 2004 A1
20040086542 Hossainy et al. May 2004 A1
20040113306 Rapacki et al. Jun 2004 A1
20040127932 Shah Jul 2004 A1
20040127970 Saunders et al. Jul 2004 A1
20040127978 Sparer et al. Jul 2004 A1
20040158276 Barbut et al. Aug 2004 A1
20040162576 Barbut et al. Aug 2004 A1
20040164030 Lowe et al. Aug 2004 A1
20040170685 Carpenter et al. Sep 2004 A1
20050004654 Khosravi et al. Jan 2005 A1
20050004684 Cribbs Jan 2005 A1
20050010170 Shanley et al. Jan 2005 A1
20050010275 Sahatjian et al. Jan 2005 A1
20050012171 Hiyama et al. Jan 2005 A1
20050021131 Venkatraman et al. Jan 2005 A1
20050038505 Shulze et al. Feb 2005 A1
20050100577 Parker et al. May 2005 A1
20050112171 Tang et al. May 2005 A1
20050143817 Hunter et al. Jun 2005 A1
20050154451 Hezi-Yamit et al. Jul 2005 A1
20050154452 Hezi-Yamit et al. Jul 2005 A1
20050154455 Hezi-Yamit et al. Jul 2005 A1
20050177246 Datta et al. Aug 2005 A1
20050187608 O'Hara Aug 2005 A1
20050233061 Schwarz Oct 2005 A1
20050254451 Grosbach Nov 2005 A1
20050254455 Plehn et al. Nov 2005 A1
20060020330 Huang et al. Jan 2006 A1
20060024373 Shahar et al. Feb 2006 A1
20060025852 Armstrong et al. Feb 2006 A1
20060036316 Zeltinger et al. Feb 2006 A1
20060041271 Bosma et al. Feb 2006 A1
20060045901 Weber Mar 2006 A1
20060051390 Schwarz Mar 2006 A1
20060051394 Moore et al. Mar 2006 A1
20060052859 Igaki Mar 2006 A1
20060058832 Melzer et al. Mar 2006 A1
20060058863 LaFont et al. Mar 2006 A1
20060063316 Yamagata et al. Mar 2006 A1
20060067974 Labrecque et al. Mar 2006 A1
20060069427 Savage et al. Mar 2006 A1
20060076708 Huang et al. Apr 2006 A1
20060085062 Lee et al. Apr 2006 A1
20060122522 Chavan et al. Jun 2006 A1
20060122686 Gilad et al. Jun 2006 A1
20060136043 Cully et al. Jun 2006 A1
20060142736 Hissink et al. Jun 2006 A1
20060147491 DeWitt et al. Jul 2006 A1
20060149365 Fifer et al. Jul 2006 A1
20060193891 Richard Aug 2006 A1
20060212064 Shah Sep 2006 A1
20060229660 Pal et al. Oct 2006 A1
20060241675 Johnson et al. Oct 2006 A1
20060241676 Johnson et al. Oct 2006 A1
20060241677 Johnson et al. Oct 2006 A1
20060241678 Johnson et al. Oct 2006 A1
20060241679 Johnson et al. Oct 2006 A1
20060241680 Johnson et al. Oct 2006 A1
20060248871 Johnson et al. Nov 2006 A1
20060259133 Sowinski et al. Nov 2006 A1
20060287715 Atladottir et al. Dec 2006 A1
20070032816 O'Connell et al. Feb 2007 A1
20070038226 Galdonik et al. Feb 2007 A1
20070038241 Pal Feb 2007 A1
20070038290 Huang et al. Feb 2007 A1
20070088383 Pal et al. Apr 2007 A1
20070100430 Rudakov et al. May 2007 A1
20070106361 Epstein May 2007 A1
20070110889 Sundar May 2007 A1
20070185561 Schmitz et al. Aug 2007 A1
20070202046 Dave Aug 2007 A1
20070250153 Cully et al. Oct 2007 A1
20070281117 Kaplan et al. Dec 2007 A1
20070283552 Gale et al. Dec 2007 A1
20080051866 Chen et al. Feb 2008 A1
20080091275 Ducharme Apr 2008 A1
20080097620 Venkatraman et al. Apr 2008 A1
20080103584 Su et al. May 2008 A1
Foreign Referenced Citations (50)
Number Date Country
10162971 Jan 2010 CN
4030998 Apr 1991 DE
0894505 Feb 1999 EP
0754017 Jun 2002 EP
1287790 Mar 2003 EP
1301221 Apr 2003 EP
1372530 Jan 2004 EP
1639962 Mar 2006 EP
2322118 May 2011 EP
2355755 Aug 2011 EP
2493419 Sep 2012 EP
11-188110 Jul 1999 JP
2002-525166 Aug 2002 JP
2005-525170 Aug 2005 JP
2007-517587 Jul 2007 JP
2009-507528 Feb 2009 JP
WO 9717100 May 1997 WO
WO 9742879 Nov 1997 WO
WO 9846297 Oct 1998 WO
WO 9942528 Aug 1999 WO
WO 9965420 Dec 1999 WO
WO 0013737 Mar 2000 WO
WO 0018328 Apr 2000 WO
WO 0044308 Aug 2000 WO
WO 0066031 Nov 2000 WO
WO 0101886 Jan 2001 WO
WO 0110342 Feb 2001 WO
WO 0128454 Apr 2001 WO
WO 0211812 Feb 2002 WO
WO 0236045 May 2002 WO
WO 02076340 Oct 2002 WO
WO 03094796 Nov 2003 WO
WO 2004110315 Dec 2004 WO
WO 2005002646 Jan 2005 WO
WO 2005004249 Jan 2005 WO
WO 2005070335 Aug 2005 WO
WO 2005077303 Aug 2005 WO
WO 2005079301 Sep 2005 WO
WO 2006009883 Jan 2006 WO
WO 2006015161 Feb 2006 WO
WO 2006019634 Feb 2006 WO
WO 2006020425 Feb 2006 WO
WO 2006020616 Feb 2006 WO
WO 2006029012 Mar 2006 WO
WO 2006036982 Apr 2006 WO
WO 2006068981 Jun 2006 WO
WO 2006074163 Jul 2006 WO
WO 2006093608 Sep 2006 WO
WO 2006107939 Oct 2006 WO
WO 2007140320 Dec 2007 WO
Non-Patent Literature Citations (14)
Entry
Eliaz et al., J. Biomed. Mater. Res., 2000, vol. 50:388-396.
Tamai, Hideo et al, “Initial and 6-Month Results of Biodegradable Poly-l-Lactic Acid Coronary Stents in Humans.” Circulation, 102(4): 399-404, Jul. 25, 2000.
De Scheerder et al., “Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries,” Atherosclierosis, vol. 114(1) pp. 105-114, Apr. 7, 1995.
Kim et al., “Nonthrombogenic polymers: pharmaceutical approaches,” Am Soc Artif Intern Organs J, vol. 6, pp. 76-87, 1983.
Kruzynska-Frejtag et al., “Periostin is expressed within the developing teeth at the sites of epithelial-mesenchymal interaction”, Dev. Dyn., vol. 229(4), pp. 857-868, Apr. 2004.
Merrill et al., “Properties of materials affecting the behavior of blood at their surfaces,” Ann NY Acad Sci, vol. 283, pp. 6-16, Feb. 1977.
Petas et al., “Effects of biodegradable self-reinforced polyglycolic acid, poly-DL-lactic acid and stainless-steel spiral stents on uroepithelium after Nd:YAG laser irradiation of the canine prostate,” BR J. Urol., vol. 80(6), pp. 903-907, Dec. 1997.
Rafanan “Stenting of the tracheobronchial tree,” Radiol Clin North Am., vol. 38(2), pp. 395-408, Mar. 2000.
Schellhammer et al., “Poly-Lactic-Add Coating for Endovascular Stents: Preliminary Results in Canine Experimental Arteriovenous Fistulae [Preliminary Report],” Invest Radiol., vol. 32(3), pp. 180-186, Mar. 1997.
Sofia Poly(Ethylene Glycol) Chemistry and Biological Applications, Ch. 22, pp. 342-360, American Chemical Society, vol. 680, Aug. 1997.
Szycher “Review of Cardiovascular Devices,” J. Biomat Appln, vol. 12, pp. 321-364, 1998.
Tamai et al, “Initial and 6-Month Results of Biodegradable Poly-I-Lactic Acid Coronary Stents in Humans,” Circulation, vol. 102(4), pp. 399-404, Jul. 25, 2000.
Webb et al., “Relative importance of surface wettability and charged functional groups on NIH 3T3 fibroblast attachment, spreading, and cytoskeletal organization”, J. Biomed Mat Res, vol. 41(3), pp. 422-430, Sep. 5. 1998.
Tan et al., “Effect of plasticization on heparin release from biodegradable matrices”, Int. J. Pharm., vol. 283(102), pp. 89-96, Sep. 28, 2004.
Related Publications (2)
Number Date Country
20070299510 A1 Dec 2007 US
20120179242 A9 Jul 2012 US
Provisional Applications (1)
Number Date Country
60808558 May 2006 US
Continuation in Parts (1)
Number Date Country
Parent 10867617 Jun 2004 US
Child 11753896 US